
US-based Cardio Flow, pioneering a novel approach to orbital atherectomy.
Cardio Flow, founded in Saint Paul, United States, is an early-stage development company dedicated to revolutionizing the treatment of peripheral artery disease (PAD) through its innovative approach to orbital atherectomy. The company's core mission is to improve patient outcomes by providing advanced medical devices that offer a safer and more effective method for removing arterial plaque. Cardio Flow's flagship product, the FreedomFlow platform, is designed for use by physicians and clinics to enhance the debulking process in PAD treatments.
Notable figures associated with Cardio Flow include leading medical professionals and experienced industry investors who support its mission. The company has achieved significant milestones, including successful clinical trials such as FAST I and FAST II, which have demonstrated the effectiveness of the FreedomFlow platform. Cardio Flow's impact lies in its potential to transform the standard of care for PAD patients, offering a promising alternative to existing atherectomy techniques and improving overall vascular health outcomes.

Native Cardio
nativecardio.com

Flow Medical
flowmedical.co

CardioFocus
cardiofocus.com

Heartflow

Reflow Medical
reflowmedical.com

MicroPort CardioFlow

ClearFlow
clearflow.com

FastWave Medical

Free Flow Medical

CardieX
cardiex.com

CardioOptics

International Cardio
hifu-rx.com

Traverse Vascular

Starlight Cardiovascular

Micro Medical Solutions
Companies similar to Cardio Flow include Native Cardio, Flow Medical, CardioFocus and Heartflow.
Cardio Flow was founded in 2014.
Cardio Flow's headquarters is located in Saint Paul, MN, US.
Cardio Flow's most recent funding round was for $1.2M (USD) in September 2023.
As of Sep 11, 2023, Cardio Flow has raised a total of $17.6M (USD).
Cardio Flow has 33 employees as of Feb 5, 2024.